Crandell Keith's Form 4 filing
Neumora Therapeutics, Inc. (NMRA) · filed Oct 29, 2025
- Accession no.
- 0001012975-25-000680
- Filed
- Oct 29, 2025, 7:21 PM ET
- Trade date
- Oct 27, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $5.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crandell KeithCIK 0001219039 | 10% Owner |
| Nelsen RobertCIK 0001219042 | 10% Owner |
| Bybee ClintonCIK 0001219043 | 10% Owner |
| Gillis StevenCIK 0001229592 | 10% Owner |
| ARCH Venture Fund XII, L.P.CIK 0001906837 | 10% Owner |
| ARCH Venture Partners XII, LLCCIK 0001979548 | 10% Owner |
| ARCH Venture Partners XII, L.P.CIK 0001979765 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 27, 2025 | Common Stock | PPurchaseAcquired | +1,915,700 | $2.61 | +$4,999,977 | 6,046,907 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This Form 4 is filed jointly by ARCH X, AVP X LP, ARCH X Overage, AVP X Overage LP, AVP X LLC, ARCH VII, AVP VII LP, AVP VII LLC, ARCH VIII Overage, AVP VIII LLC, ARCH XII, AVP XII LP, AVP XII LLC, Robert Nelsen, Steven Gillis, Keith Crandell, Clinton Bybee (collectively, the "Reporting Persons"). Kristina Burow has direct ownership of Common Stock and is filing her own Form 4 separately.